Results 181 to 190 of about 1,127,448 (336)

Synthesis of New N,N′‐Diarylureas and Their Theoretical Study as Cannabinoid‐1 Receptor Inhibitors

open access: yesChemPlusChem, EarlyView.
A series of new pyrazolo‐ and triazolo‐based N,N′‐diarylureas is synthesized following the triphosgene protocol in the last step. Density functional theory calculations and molecular docking provide strong evidence that all new compounds bind strongly to the cannabinoid‐1 (CB‐1) receptor, showing comparable results with the known allosteric CB‐1 ...
Eirini Tsemperlidou   +4 more
wiley   +1 more source

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman   +14 more
wiley   +1 more source

Lower Gastrointestinal Bleeding

open access: yesDeckerMed Surgery, 2020
John R. Saltzman, Jennifer Nayor
openaire   +1 more source

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy